Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma

Vismodegib, a hedgehog pathway inhibitor, has been used in the management of locally advanced basal cell carcinoma (BCC) not suitable for surgery or radiation therapy. We report our experience using neoadjuvant vismodegib for locally advanced periocular BCC, followed by surgical excision. Our aim was to assess the effect on the extent of surgical excision and histological response.A retrospective case series of patients treated with neoadjuvant...